SG11202007925SA - Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders - Google Patents
Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disordersInfo
- Publication number
- SG11202007925SA SG11202007925SA SG11202007925SA SG11202007925SA SG11202007925SA SG 11202007925S A SG11202007925S A SG 11202007925SA SG 11202007925S A SG11202007925S A SG 11202007925SA SG 11202007925S A SG11202007925S A SG 11202007925SA SG 11202007925S A SG11202007925S A SG 11202007925SA
- Authority
- SG
- Singapore
- Prior art keywords
- lma
- treat
- binding proteins
- autoimmune disorders
- expressing cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018900534A AU2018900534A0 (en) | 2018-02-20 | Composition and method | |
| PCT/AU2019/050137 WO2019161443A1 (en) | 2018-02-20 | 2019-02-20 | Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007925SA true SG11202007925SA (en) | 2020-09-29 |
Family
ID=67686653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007925SA SG11202007925SA (en) | 2018-02-20 | 2019-02-20 | Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11447571B2 (en) |
| EP (1) | EP3755724A4 (en) |
| JP (2) | JP7490559B2 (en) |
| KR (1) | KR20210005553A (en) |
| CN (1) | CN111918879A (en) |
| AU (2) | AU2019225446B2 (en) |
| BR (1) | BR112020017018A2 (en) |
| CA (1) | CA3091711A1 (en) |
| SG (1) | SG11202007925SA (en) |
| WO (1) | WO2019161443A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023242634A1 (en) * | 2022-06-13 | 2023-12-21 | Paradox Immunotherapeutics Inc. | Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005082409A1 (en) | 2004-02-27 | 2005-09-09 | Pacmab Limited | Target for b-cell disorders |
| US20100187181A1 (en) * | 2009-01-29 | 2010-07-29 | Sortwell Edwin T | Method for Dispersing and Aggregating Components of Mineral Slurries |
| MY183617A (en) | 2009-04-07 | 2021-03-03 | Immune System Therapeutics Ltd | Method for treating immune disorders |
| GB201203938D0 (en) | 2012-03-06 | 2012-04-18 | Binding Site Group The Ltd | Assay system |
-
2019
- 2019-02-20 SG SG11202007925SA patent/SG11202007925SA/en unknown
- 2019-02-20 EP EP19758107.7A patent/EP3755724A4/en active Pending
- 2019-02-20 KR KR1020207027033A patent/KR20210005553A/en not_active Application Discontinuation
- 2019-02-20 BR BR112020017018-6A patent/BR112020017018A2/en unknown
- 2019-02-20 CA CA3091711A patent/CA3091711A1/en active Pending
- 2019-02-20 AU AU2019225446A patent/AU2019225446B2/en active Active
- 2019-02-20 CN CN201980012636.9A patent/CN111918879A/en active Pending
- 2019-02-20 WO PCT/AU2019/050137 patent/WO2019161443A1/en unknown
- 2019-02-20 JP JP2020544005A patent/JP7490559B2/en active Active
- 2019-02-20 US US16/970,991 patent/US11447571B2/en active Active
-
2021
- 2021-04-06 AU AU2021202092A patent/AU2021202092A1/en not_active Abandoned
-
2022
- 2022-08-12 US US17/819,483 patent/US20230174675A1/en active Pending
-
2024
- 2024-05-15 JP JP2024079382A patent/JP2024100838A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020017018A2 (en) | 2020-12-29 |
| US20210230309A1 (en) | 2021-07-29 |
| JP2021514369A (en) | 2021-06-10 |
| CN111918879A (en) | 2020-11-10 |
| JP7490559B2 (en) | 2024-05-27 |
| CA3091711A1 (en) | 2019-08-29 |
| AU2019225446A1 (en) | 2020-10-08 |
| JP2024100838A (en) | 2024-07-26 |
| EP3755724A1 (en) | 2020-12-30 |
| WO2019161443A1 (en) | 2019-08-29 |
| EP3755724A4 (en) | 2022-03-23 |
| AU2021202092A1 (en) | 2021-04-29 |
| AU2019225446B2 (en) | 2021-01-07 |
| US11447571B2 (en) | 2022-09-20 |
| KR20210005553A (en) | 2021-01-14 |
| US20230174675A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275782A (en) | Multispecific antigen binding proteins and methods of use thereof | |
| IL281783A (en) | Sirpα binding proteins and methods of use thereof | |
| IL276537A (en) | Antibodies binding to gprc5d | |
| IL287045A (en) | B cell maturation antigen binding proteins | |
| IL276164A (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| IL281683A (en) | Dll3 binding proteins and methods of use | |
| IL276457A (en) | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells | |
| IL283939A (en) | Antibodies binding to cd3 | |
| IL263083B1 (en) | Single chain variable fragment cd3 binding proteins and use thereof in treatment of cancer | |
| IL281441A (en) | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer | |
| IL281449A (en) | Anti-ifnar1 antibodies for treating autoimmune diseases | |
| IL279201A (en) | Multi-specific binding proteins and methods of use thereof | |
| GB201802338D0 (en) | Antigen binding proteins | |
| IL284156A (en) | Anti-ctla-4 binding proteins and methods of use thereof | |
| TN2015000415A1 (en) | Anti-cd52 antibodies | |
| IL281351A (en) | Improved anti-flt3 antigen binding proteins | |
| IL289145A (en) | Il1rap binding proteins | |
| PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
| SG11202007925SA (en) | Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders | |
| IL291364A (en) | Antigen binding proteins | |
| IL279109A (en) | Therapeutic antibodies binding to biantennary lewis b and lewis y antigens | |
| GB201804531D0 (en) | Antigen binding proteins | |
| KR102293335B9 (en) | Lxr rna rna rna aptamer specifically binding to lxr protein and using the same |